Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Acambis Live Smallpox Vaccine Wins FDA Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

ACAM2000 gained unanimous support of FDA’s Vaccines and Related Biological Products Advisory Committee in May.

You may also be interested in...



Stockwatch: Earnings Season Catches An Early Cold As Coronavirus Sweeps In

As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.

Sanofi Pasteur Will Fund Development Of Acambis West Nile Vaccine

Acambis is hoping to accelerate development of ChimeriVax and be first to market with a West Nile vaccine after inking an agreement with Sanofi Pasteur that includes $10 million upfront and $70 million in milestones.

Sanofi Pasteur Will Fund Development Of Acambis West Nile Vaccine

Acambis is hoping to accelerate development of ChimeriVax and be first to market with a West Nile vaccine after inking an agreement with Sanofi Pasteur that includes $10 million upfront and $70 million in milestones.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS066676

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel